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Mutations that increase the protein kinase activity of LRRK2 are one of the most common
causes of familial Parkinson’s disease. LRRK2 phosphorylates a subset of Rab GTPases
within their Switch-II motif, impacting interaction with effectors. We describe and validate
a new, multiplexed targeted mass spectrometry assay to quantify endogenous levels of
LRRK2-phosphorylated Rab substrates (Rab1, Rab3, Rab8, Rab10, Rab35 and Rab43)
as well as total levels of Rabs, LRRK2 and LRRK2-phosphorylated at the Ser910 and
Ser935 biomarker sites. Exploiting this assay, we quantify for the first time the relative
levels of each of the pRab proteins in different cells (mouse embryonic fibroblasts, human
neutrophils) and mouse tissues (brain, kidney, lung and spleen). We define how these
components are impacted by Parkinson’s pathogenic mutations (LRRK2[R1441C] and
VPS35[D620N]) and LRRK2 inhibitors. We find that the VPS35[D620N], but not LRRK2
[R1441C] mutation, enhances Rab1 phosphorylation in a manner blocked by administra-
tion of an LRRK2 inhibitor, providing the first evidence that endogenous Rab1 is a
physiological substrate for LRRK2. We exploit this assay to demonstrate that in
Parkinson’s patients with VPS35[D620N] mutations, phosphorylation of multiple Rab pro-
teins (Rab1, Rab3, Rab8, Rab10 and Rab43) is elevated. We highlight the benefits of this
assay over immunoblotting approaches currently deployed to assess LRRK2 Rab signal-
ling pathway.
Introduction
Autosomal dominant mutations that hyperactivate leucine-rich repeat kinase 2 (LRRK2) are a frequent
cause of late-onset familial Parkinson’s disease [1,2]. LRRK2 is a large multi-domain enzyme made up
of armadillo, ankyrin, leucine-rich repeats, tandem Roco type GTPase, Ser/Thr kinase domains, and a
C-terminal WD40 domain [3,4]. Recent tomography and cryo-EM analysis provide the first glimpse
of the LRRK2 structure revealing how Parkinson’s mutations and inhibitors modulate the closed and
open conformation of the kinase and impact upon microtubule binding [5,6]. The best-characterized
substrates of LRRK2 comprise a subset of Rab GTPases, namely Rab3A, Rab3B, Rab3C, Rab3D,
Rab8A, Rab8B, Rab10, Rab12, Rab29, Rab35 and Rab43 [7,8]. LRRK2 phosphorylates these Rab pro-
teins at a conserved Ser/Thr residue (Thr72 for Rab8A and Thr73 for Rab10) located within the
effector-binding Switch-II motif. In addition, LRRK2 efficiently phosphorylates Rab1 in vitro and in
overexpression studies at the equivalent residue (Thr75) [8,9], but thus far, we have not observed
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LRRK2-phosphorylated Rab proteins lose their ability to bind their cognate effector proteins, and instead
interact with new sets of phospho-binding effectors such as RILPL1/2 and JIP3/4 [7,10]. LRRK2 suppresses
ciliogenesis in striatal cholinergic interneurons through LRRK2-phosphorylated Rab10 forming a complex with
RILPL1 [11,12]. Recent evidence also points towards LRRK2 controlling lysosomal and endomembrane homeo-
stasis through its ability to phosphorylate Rab8A [13,14]. Parkinson’s causing D620N autosomal dominant
mutation in the VPS35, the cargo binding subunit of the retromer complex also elevates LRRK2 mediated Rab
protein phosphorylation through an unknown mechanism [15].
Various, dominantly inherited pathogenic mutations within the Roc (N1437H, R1441G/C/H), Cor
(Y1699C), and kinase (G2019S, I2020T) domains of LRRK2 have been well-characterized [16]. The G2019S
mutation is located in the conserved Mg2+ subdomain VII motif of the kinase domain and represents the most
commonly observed pathogenic mutation [17]. All LRRK2 pathogenic mutations enhance phosphorylation of
Rab10 and several of the other Rab protein substrates studied, typically between 1.5 to 4-fold [7,8,18,19].
Pathogenic mutations also stimulate LRRK2 autophosphorylation at Ser1292 [20]. However, stoichiometry of
Ser1292 phosphorylation is extremely low, making it hard to detect and quantify robustly, especially for
endogenous LRRK2 using available phospho-specific antibodies [21]. Standard mass spectrometry approaches
are also rendered difficult as the tryptic peptide encompassing Ser1292 lies within a two amino acid phospho-
peptide. LRRK2 is also phosphorylated on several well studied serine residues including Ser910 and Ser935,
located between the ankyrin and leucine rich repeats that regulate 14-3-3 binding [22]. These sites become
rapidly dephosphorylated upon pharmacological inhibition of LRRK2 [23], and have thus been widely used to
assess the target engagement of LRRK2 inhibitors [24]. Phosphorylation of Ser910 and Ser935 does not correl-
ate with intrinsic LRRK2 kinase activity and moreover, several pathogenic mutations including R1441C/G sup-
press the phosphorylation of these residues through an unknown mechanism [22,23].
Measurement of Rab protein phosphorylation is the gold-standard approach to readout the steady-state activity
of endogenous LRRK2 pathway in cell or tissue extracts. Global mass spectrometry (MS) analysis points towards
Rab8A and Rab10 comprising the most abundant LRRK2 Rab substrates in cells and tissues analyzed [8]. Recent
work employing a sensitive, targeted MS-based assay established that stoichiometry of Rab10 Thr73 phosphoryl-
ation is low, typically 1–3% [25]. It is likely that stoichiometry of other LRRK2-phosphorylated Rab proteins will
be significantly lower. Most widely utilized current approaches to assess LRRK2 mediated Rab protein phosphor-
ylation rely on antibody-based approaches. Thus far, selective phospho-Rab monoclonal antibodies have been
developed that specifically detect pRab10 phosphorylated at Thr73 [26] and Rab12 phosphorylated at Ser105
[15]. In addition, a pan-selective phospho-antibody detecting Rab proteins phosphorylated on Thr residues (Rab1
Rab3, Rab8, Rab10, Rab35 and Rab43) has been described [26]. This pan-selective pRab antibody has been
exploited to immunoprecipitate multiple LRRK2-phosphorylated Rab proteins that can then be detected by
immunoblot or MS analysis [7,27]. This antibody, however, does not detect LRRK2 substrates Rab12 or Rab29
that are phosphorylated on Ser residues [26].
Here, we describe a new multiplexed targeted Parallel Reaction Monitoring (PRM) [28], MS assay designed
to quantity multiple LRRK2-phosphorylated Rab proteins in a single assay. This assay permits simultaneous
quantitation of endogenous LRRK2-phosphorylated Rab1, Rab3, Rab8, Rab10, Rab35 and Rab43 in 0.1 to 1 mg
of cell or tissue extract. Our assay also quantifies total levels of Rab proteins and LRRK2 in addition to
LRRK2-phosphorylated Ser910 and Ser935. Employing this assay, we are able to quantify the relative abun-
dance of the different pRab proteins in multiple cells and tissues, defining the impact of LRRK2 inhibitors and
Parkinson’s disease-causing mutations.
Materials and methods
A comprehensive list of reagents, antibodies, cDNA constructs, mice, cell lines, buffers, equipment, software
packages utilized in this study are provided in Supplementary File S1.
Cell culture, treatments and lysis
MEFs were cultured in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% (v/v) fetal calf
serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, non-essential amino acids and 1 mM
sodium pyruvate. All cells were grown at 37°C and 5% (v/v) CO2 in a humidified atmosphere. Cell lines utilized
for this study were tested regularly for mycoplasma contamination and confirmed as negative prior to experi-
mental analysis. Cells were lysed in ice-cold lysis buffer containing 50 mM Tris–HCl pH 7.4, 1 mM EGTA,
1 mM sodium orthovanadate, 10 mM 2-glycerophosphate, 50 mM NaF, 5 mM sodium pyrophosphate, 270 mM
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sucrose, supplemented with 1 mg/ml microcystin-LR, 1 mM sodium orthovanadate, complete EDTA-free prote-
ase inhibitor cocktail (Roche), and 1% (v/v) Triton X-100. Lysates were clarified by centrifugation for 20 min at
20 800 g at 4°C. The supernatant was collected in protein lo binding Eppendorf-tubes (#022431081). We have
used protein lo binding tubes and non-autoclaved tips for all of the LC–MS/MS analysis to avoid any contam-
ination leaching from autoclaved plastic ware which could affect the LC–MS/MS analysis. Protein concentra-
tions of cell lysates were determined using the Bradford assay. The lysates were flash-frozen in liquid nitrogen
and stored at −80°C.
Generation of mouse embryonic fibroblasts
Wild-type and homozygous MEFs were isolated from littermate-matched mouse embryos at day E12.5, as
described in a previous study resulting from crosses between heterozygous mice [29]. Wild-type and homozy-
gous LRRK2 [R1441C] [7], VPS35[D620N] [15] and LRRK2 [G2019S] MEFs have been described previously.
Neutrophil isolation
Neutrophils were isolated from peripheral human blood from healthy donors and Parkinson’s patients with
VPS35[D620N] mutations as described previously [30]. For the experimental part of our study using human
material, blood was collected with ethical approval for non-clinical research involving human participants
granted by the Institutional Review Board of the Medical University of Vienna in Austria, EK Nr: 2195/2016
(for Figure 10) or the School Research Ethics Committee, University of Dundee, 19/96 (for Supplementary
Figure S12). All participants provided informed consent. Viability and cell lysis performed as described previ-
ously [30]. Briefly, Neutrophils were isolated from freshly drawn whole blood from 3 donors (25 ml per donor)
using the EasySep Direct Human Neutrophil Isolation Kit and Easy 50 EasySep Magnet (Stemcell) as described
[30,31]. After isolation, neutrophils from each donor were resuspended in RPMI and treated with either the
indicated concentration of MLi-2 or DMSO (0.1% v/v). After 1h, cells were harvested in 100 ml per sample of
ice-cold lysis buffer supplemented with the potent protease inhibitor diisopropylfluorophosphate (DIFP) to a
final concentration of 0.5 mM, that was added to lysis buffer just before lysing cells [31].
Mice
Mice were maintained under specific pathogen-free conditions at the University of Dundee (U.K.). All animal
studies were ethically reviewed and carried out in accordance with Animals (Scientific Procedures) Act 1986
and regulations set by the University of Dundee and the U.K. Home Office. Animal studies and breeding were
approved by the University of Dundee ethical committee and performed under a U.K. Home Office project
license. Mice were multiply housed at an ambient temperature (20–24°C) and humidity (45–55%) and main-
tained on a 12 h light/12 h dark cycle, with free access to food (SDS RM No. 3 autoclavable) and water. For the
experiments described in Figure 9 and Supplementary Figure S11 (VPS35[D620N] knock-in model), in
Figure 8 and Supplementary Figure S10 (LRRK2[R1441C] knock-in model), 6-month-old littermate matched
were injected subcutaneously with vehicle [40% (w/v) (2-hydroxypropyl)-β-cyclodextrin (Sigma–Aldrich
#332607)] or MLi-2 dissolved in vehicle at a 30 mg/kg final dose. Mice were sacrificed by cervical dislocation
2 h following treatment. Tissues were immediately harvested and snap-frozen in liquid nitrogen.
Mouse genotyping
Genotyping of mice was performed by the MRC genotyping team at the MRC-PPU, University of Dundee, by
PCR using genomic DNA isolated from ear biopsies. The VPS35[D620N] knock-in mouse strain required
Primer 1 (50 TCATTCTGTGGTTAGTTCAGTTGAG 30), Primer 2 (50 CCTCTAACAACCAAGAGGAACC 30),
and Primer 3 (50 ATTGCATCGCATTGTCTGAG 30) to distinguish wild-type from D620N knock-in alleles
(60°C annealing temp). The LRRK2[R1441C] knock-in mouse strain required Primer 1 (50 CTGCAGGCTACT-
AGATGGTCAAGGT 30) and Primer 2 (50 CTAGATAGGACCGAGTGTCGCAGAG 30) to identify wild-type
and R1441C knock-in alleles (60°C annealing temp). All genotyping primers were used at a final concentration
of 10 pmol/ml. PCR reactions were set up and run using KOD Hot Start Polymerase standard protocol. PCR
bands were visualized on Qiaexcel (Qiagen) using the standard DNA screening kit cartridge.
Preparation of mouse tissue lysates
Snap frozen tissues were weighed and thawed on ice in a 10-fold volume excess of in ice-cold lysis buffer con-
taining 50 mM Tris–HCl pH 7.4, 1 mM EGTA, 1 mM sodium orthovanadate, 10 mM 2-glycerophosphate,
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50 mM NaF, 5 mM sodium pyrophosphate, 270 mM sucrose, supplemented with 1 mg/ml microcystin-LR,
1 mM sodium orthovanadate, complete EDTA-free protease inhibitor cocktail (Roche), and 1% (v/v) Triton
X-100. Tissue was homogenized using a POLYTRON homogenizer (KINEMATICA), employing 3 rounds of
10 s homogenization with 10 s intervals on ice. Lysates were centrifuged at 20 800 g for 30 min at 4°C and
supernatant was collected for subsequent Bradford assay and immunoblot analysis.
Quantitative immunoblot analysis
Clarified cell or tissue extracts were mixed with a quarter of a volume of 4× SDS–PAGE loading buffer
[250 mM Tris–HCl, pH 6.8, 8% (w/v) SDS, 40% (v/v) glycerol, 0.02% (w/v) Bromophenol Blue and 4% (v/v)
2-mercaptoethanol]. An amount of 10–30 mg of samples were loaded onto NuPAGE 4–12% Bis-Tris Midi Gel
(Thermo Fisher Scientific, Cat# WG1403BOX) and electrophoresed at 130 V for 2 h with the NuPAGE MOPS
SDS running buffer (Thermo Fisher Scientific, Cat# NP0001-02). At the end of electrophoresis, proteins were
electrophoretically transferred onto the nitrocellulose membrane (GE Healthcare, Amersham Protran
Supported 0.45 mm NC) at 100 V for 90 min on ice in the transfer buffer (48 mM Tris–HCl and 39 mM
glycine). Transferred membrane was blocked with 5% (w/v) skim milk powder dissolved in TBS-T [20 mM
Tris–HCl, pH 7.5, 150 mM NaCl and 0.1% (v/v) Tween 20] at room temperature for 1 h. The membrane was
typically cropped into three pieces, namely the ‘top piece’ (from the top of the membrane to 75 kDa), the
‘middle piece’ (between 75 and 30 kDa) and the ‘bottom piece’ (from 30 kDa to the bottom of the membrane).
The top piece was incubated with rabbit anti-LRRK2 pS935 UDD2 antibody multiplexed with mouse
anti-LRRK2 C-terminus total antibody diluted in 5% (w/v) skim milk powder in TBS-T to a final concentration
of 1 mg/ml for each of the antibody. The middle piece was incubated with mouse anti-GAPDH antibody
diluted in 5% (w/v) skim milk powder in TBS-T to a final concentration of 50 ng/ml. The bottom pieces were
incubated with rabbit MJFF-pRab10-clone-1 monoclonal antibody multiplexed with mouse MJFF-total
Rab10clone-1 monoclonal antibody diluted in 2% (w/v) bovine serum albumin in TBS-T to a final concentra-
tion of 0.5 mg/ml for each of the antibody. All blots were incubated in primary antibody overnight at 4°C. Prior
to secondary antibody incubation, membranes were washed three times with TBS-T for 10 min each. The top
and bottom pieces were incubated with goat anti-mouse IRDye 680LT (#926-68020) secondary antibody multi-
plexed with goat anti-rabbit IRDye 800CW ((#926-32211) secondary antibody diluted in TBS-T (1:10 000 dilu-
tion) for 1 h at room temperature. The middle piece was incubated with goat anti-mouse IRDye 800CW
(#926-32210) secondary antibody diluted in TBS-T (1 : 10 000 dilution) at room temperature for 1 h.
Membranes were washed with TBS-T for three times with a 10 min incubation for each wash. Protein bands
were acquired via near infrared fluorescent detection using the Odyssey CLx imaging system and quantified
using the Image Studio software.
Limit of detection experiments
The generation of A549 Rab10 [18] and Rab8A [7] knock-out cells have been described previously
(Supplementary Figure S2A). An amount of 10 mg of wild-type, Rab8A knock-out and Rab10 knock-out cell
extract was reduced by adding final 10 mM DTT (Dithiothreitol) and incubated 56°C for 20 min and alkylated
by adding 20 mM Iodoacetamide. After incubating in the dark for 30 min at room temperature proteins were
acetone precipitated, resolubilized in 6 M Urea buffer in 50 mM TEABC pH 8.0, digested using trypsin (1 : 20
ratio) and desalted using C18 cartridges as described previously [32]. The peptide amounts were determined by
3-(4-carboxybenzoyl)quinoline-2-carboxaldehyde (CBQCA) method [33]. An amount of 150 mg aliquots of
each digest were lyophilized and stored at −80°C until further immunoprecipitation experiments using
Pan-pRab antibody.
Bovine Serum Albumin tryptic digest
An amount of 30 mg of Bovine serum Albumin was dissolved in 6 M Urea in 50 mM TEABC pH 8.0 buffer,
reduced and alkylated using 5 mM DTT and 20 mM Iodoacetamide followed by incubation 30 min in the dark.
The Urea concentration was reduced to 2 M using 50 mM TEABC pH 8.0 and digested with trypsin (1 : 20
ratio) at room temperature for 16 h. The digest was acidified by adding TFA to 1% (v/v) and desalted using
C18 Sep-Pak cartridges ([32]. Peptide amounts were determined by CBQCA assay [33] and 2 mg aliquots were
lyophilized and stored at −80°C.
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Pan-pRab immunoprecipitation to assess Rab1 phosphorylation by
immunoblotting
To assess Rab1 phosphorylation, 12.5 mg of the Pan-pRab antibody was coupled to 25 ml of Protein A/G
Sepharose beads for 1 h at 4°C with agitation. This was incubated with 2.3 mg of indicated MEF extract for 2 h
at 4°C. The immunoprecipitate was washed three times with lysis buffer. The immunoprecipitate was incubated
in 20 ml of 2X NuPAGE LDS sample buffer and centrifuged through Spin-X column to remove resin. The
eluate was used for detecting Rab1-Total (80% of sample) and Rab10-Total (20% of sample) by immunoblot-
ting. We also undertook validation of novel stressMarq biosciences Rab1 total antibody (Supplementary
Figure S5C). Lysates of HEK293 cells overexpressing HA-Rab1A, HA-Rab1B, HA-Rab1C or HA-empty were
used for HA immunoprecipitation (300 μg per IP). Immunoprecipitates were then immunoblotted with the
Rab1-total and ant-HA antibodies. Immunoblots were subjected to quantitative LI-COR immunoblot analysis
with all indicated antibodies at 1 mg/ml. The Rab1 antibody detects Rab1A and Rab1B equally and Rab1C sig-
nificantly more weakly (Supplementary Figure S5C).
S-Trap assisted on-column digestion
Cell or tissue lysates (typically 250 mg) prepared as described above, was reduced by adding 10 mM Tris
(2-carboxyethyl)phosphine(TCEP) and incubated at 60°C for ∼30 min on a Thermomixer with a gentle agita-
tion (800 rpm). The samples were allowed to cool to room temperature and alkylated by adding 40 mM
Iodoacetamide and incubated in dark at room temperature for 30 min on a Thermomixer by gentle agitation
(800 rpm). The samples were supplemented sodium dodecyl sulfate (SDS) to 5% (v/v) from a stock solution of
10% (v/v) SDS and acidified by adding phosphoric acid to 1.2% (v/v) using 12% (v/v) phosphoric acid stock.
The samples were immediately added to S-Trap wash buffer (90% (v/v) methanol in 100 mM TEABC pH 7.1)
was added (seven times the volume of lysate). Under these conditions proteins form fine suspension particles
and the resulting mixture was loaded on S-Trap mini columns. The columns were then centrifuged for 1 min
at 1000 g, washed four times with S-Trap Wash buffer and transferred to 2 ml collection tubes. An ‘in-solution
on-column’ tryptic digestion was performed by applying 160 ml of 50 mM TEABC pH 8.0 containing a 1 : 15
trypsin: protein substrate applied to S-Trap column. The columns were spun down at 300 g 1 min and the flow
through reapplied to the columns and incubated on a Thermomixer at 47°C for 80 min followed by 3 h at
room temperature without agitation. The columns were transferred to a new 1.5 ml low binding Eppendorf
tube for the elution. An amount of 80 ml of 50 mM TEABC pH 8.0 was added and spun down at 1000 g for
1 min. An amount of 100 ml of 0.15% (v/v) Formic acid was added to the columns and the spun down at
1000 g 1 min. Another 100 ml of elution buffer 3 [80% (v/v) Acetonitrile and 0.15% (v/v)] was added and spun
down at 500 g for 3 min to completely elute the tryptic peptides. To ensure complete recovery, the columns
were transferred to the previous collection tubes and another 100 ml of this elution buffer 3 was added and
spun down. The eluates were combined, and peptides quantified using the CBQCA assay. For the total Rab
protein analysis 0.5 mg of the tryptic digest aliquoted. For the phospho-Rab protein analysis 150 mg of tryptic
peptide analysis was aliquoted for all cells and tissues other than brain in which 600–650 mg of tryptic peptide
was used. Samples for total Rab protein analysis and the phospho-Rab analysis were vacuum dried in a speed-
vac and stored in −80°C until MS analysis.
Preparation of heavy stable isotope peptides
All heavy and light stable isotope synthetic peptides described in Supplementary Table S1 were synthesized by JPT
peptide technologies (https://www.jpt.com/) in 1 nanomole aliquots. All the synthetic peptides were quantified by
amino acid analysis and LC–MS analysis by JPT and confirmed to be of purity of >95%. The peptides were deliv-
ered in a lyophilized form and were resuspended in solvent containing 0.1% (v/v) formic acid in 3% (v/v) aceto-
nitrile to give a final concentration of 10 pmol/ml. Aliquots of this were further diluted in a series of 10-fold
dilution to a lowest concentration of 10 fmol/ml and stocks of each dilution aliquoted and stored at −80°C.
Immunoprecipitation of pRab, total LRRK2, pSer910 and pSer935 peptides
Aliquots of vacuum-dried peptides (0.5 mg for total Rab samples and 150 mg for phospho-Rab samples) were
dissolved in 1 ml of Immunoaffinity purification buffer (50 mM MOPS, 50 mM Na2HPO4 and 150 mM NaCl).
The samples were sonicated for 10 min at room temperature, centrifuged at 20 800 g for 10 min and transferred
to a 1.5 ml low binding Eppendorf tube. A 10 ml mixture containing 100 fmol of each of the pRab1, pRab3,
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pRab8, pRab10, pRab35, pRab43, tLRRK2(388–399), LRRK2-s910 and LRRK2-pS935 heavy isotope synthetic
peptide mixture was added. Next an 10 ml suspension of Immunoaffinity purification buffer containing 50% (v/v)
Protein A/G resin conjugated to 0.5 mg PAN-pThr-Rab antibody (pRab8), 0.5 mg LRRK2 total antibody (8G10)
antibody, 0.5 mg LRRK2-pS910 (UDD1) and 0.5 mg LRRK2-pS935 (UDD2) was added. Samples were incubated
on an end-to-end rotator in 4°C for 2 h, centrifuged at 2000 g for 2 min at 4°C. The supernatant was collected
into new 1.5 ml Eppendorf tubes and subjected to a second round of immunoprecipitation as described above.
The immunoprecipitates washed sequentially 1 ml of Immunoaffinity purification buffer, two washes with 1 ml of
phosphate-buffered saline, and finally with 1 ml of Milli-Q water and the supernatant removed to leave just the
immunoprecipitate. An amount of 60 ml of 0.2% (v/v) TFA was added to the washed immunoprecipitates and
the resulting mixture incubated at room temperature on a Thermomixer at 1200 rpm for 10 min to elute
absorbed peptides. The tubes were centrifuged at 2000 g for 2 min and the supernatant containing the eluted pep-
tides collected in a new 1.5 ml Eppendorf tube. The resin was washed again with 40 ml of 0.2% (v/v) TFA and
the supernatants containing the immunoprecipitated peptides were combined and desalted using homemade C18
stage-tips.
Preparation of samples for total Rab peptide quantitation
An amount of 0.5 mg of peptide digest was dissolved in 60 ml of buffer containing (0.1% (v/v) formic acid in
3%(v/v) acetonitrile and sonicated at room temperature for 10 min. At this stage, 0.5 mg of peptide digest
spiked with an equimolar ratio of 50 fmol of heavy labelled peptide mixture containing Rab1A, Rab1B, Rab3D,
Rab8A, Rab8B, Rab10, Rab12, Rab35 and Rab43. The sample was then loaded on EvoTips as described below
were either subjected to LC–MS/MS analysis immediately or stored at 4°C.
C18-peptide clean-up of samples
C18 clean-up of the immunoprecipitated peptides prior to MS analysis employing in-house prepared Stage tips.
A single 18-gauge syringe was used to punch a hole in C18 material from 47 mm think C18 disk which was
packed into a 250 ml pipette tips. The following solvents were prepared fresh, Activation solvent (100% (v/v)
Acetonitrile); Solvent-A (0.1% (v/v) TFA); Solvent-B (50% (v/v) Acetonitrile in 0.1% (v/v) TFA). An amount of
60 ml of Activation solvent was added to the stage tip which was centrifuged at 2000 g for 2 min. Flow through
was discarded and the stage-tips were equilibrated by adding 60 ml of Solvent-A followed by centrifugation at
2000 g for 2 min and this step was repeated a further time. The acidified peptides were loaded onto the stage
tip, which was centrifuged at 1500 g for 4 min. The flow through was reapplied and centrifuged through the tip
a second time to ensure all peptides were absorbed onto the C18 resin. The stage-tips were next washed twice
by centrifugation of 60 ml of Solvent-A through the tip. Finally, the stage-tips were transferred into a new col-
lection tubes and the peptides were eluted by adding 30 ml of solvent-B and centrifuged and this step was
repeated once again, and the eluates combined. The eluate was flash frozen on a dry-ice and vacuum dried and
stored in −80°C freezer until the LC–MS/MS analysis.
Deep proteomic profiling of wild-type MEFS
An amount of 300 mg of wild-type MEFs were prepared for tryptic digestion using S-Trap assisted on-column
digestion workflow as described above. Eluted peptides were vacuum dried and subjected to basic
reverse-Phased liquid chromatography fractionation as explained previously [32]. A total of 96 fractions were
collected and concatenated to 48 fractions and further vacuum dried and stored in −80°C deep freezer until
further LC–MS/MS analysis.
Preparation of Evotips
The vacuum dried peptides were resuspended in 60 ml of Solvent (0.1% (v/v) Formic acid in 3% (v/v)
Acetonitrile) and sonicated on a water bath sonication for 4 min at room temperature. In addition, 5 ml of a
5 fmol/ml (25 fmol) of Pierce retention time correction (PRTC, Thermo Fisher Scientific #88320) was spiked-in
to the mixture to correct on-the-fly scheduled retention times of the targeted analytes on the mass spectrom-
eter. Evotips were purchased from EvoSep (Odense Denmark #EV2001). The following solvents were prepared
in fresh. Solvent-A (0.1% (v/v) Formic acid); Solvent-B (100% (v/v) Acetonitrile). The Evotips were activated
by adding 20 ml of Solvent-B which was centrifuged through the tip at 1000 g for 1 min. The Evotips were next
immersed in a 200 ml of Isopropanol for few seconds to eliminate any polymers. The tips were next equili-
brated by adding 20 ml of Solvent-A which was centrifuged through at 1000 g for 1 min and this step repeated
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once more and the eluates discarded. The acidified peptides for the total Rabs and immunoprecipitation
samples were loaded onto the Evotips which were next centrifuged at 700 g for 2 min. The Flow through was
reapplied to the tip and centrifuged again for 700 g for 2 min. The Evotips were washed by adding 20 ml of
Solvent-A, centrifuged at 1000 g for 1 min and this step repeated a further time. A final 100 ml of Solvent-A
was added and centrifuged for 4 s such that the Solvent-A protects the C18 material from evaporation during
the LC–MS/MS analysis. At this stage, the prepared EvoTips are transferred onto the 96 well plate box and
placed on EvoSep auto sampler tray.
LC–MS/MS analysis of immunoprecipitated peptides
Unless stated otherwise PRM data was acquired with the following settings. EvoTips were loaded on EvoSep LC
system auto sampler tray and analyzed using 21 min (60 samples per day) script [34]. The EvoSep LC system
elutes the peptides from EvoTip using low pressure pump-A and pump-B by directly applying 35% solvent B
(Acetonitrile in 0.1% (v/v) formic acid) the eluted peptides stored in a long capillary loop where using Pump-C
and Pump-D generates a pre-formed gradient that applies the peptides into the analytical column Reprsoil-pur
C18 AQ, 1.5 mm beads, 150 mm ID, 8 cm long for pRab analysis (21 min script) and Reprsoil-pur C18 AQ,
1.9 mm beads, 150 mm ID, 15 cm long for total Rab analysis (44 min script). The eluted peptides are sprayed
into the mass spectrometer that was operated in a PRM mode using Xcalibur software interface by including
one Full MS scan within 300–800 m/z per duty cycle. The Full MS acquired at 120 000 resolution at m/z 200
by accumulating 3 × 106 ions in the C-trap for a maximum of 20 ms. The targeted MS2 (PRM) scans were per-
formed by importing inclusion list containing pRabs, total and phospho LRRK2 and PRTC peptide sequences
m/z, charge state and scheduled retention time windows. The inclusion list containing scheduled retention
times, +2 or +3 charge states are provided in Supplementary Table S2. The PRM MS2 scans for each targeted
ion was isolated using 0.7 Da Quadrupole filter and 1 × 105 AGC target was set and accumulated in the C-trap
for 250 ms by using 27% higher energy collisional dissociation (HCD). The MS2 scans were acquired at 30 000
resolution at 200 m/z analyzed using Ultra-high field Orbitrap mass analyzer. The loop count was set to 12
scans per duty cycle. Dynamic retention time algorithm was enabled to correct on-the-fly scheduled retention
times of the target ions.
The retention times of pRabs were determined by using an equimolar mixture of 50 fmol of pRab1, pRab3,
pRab5, pRab8, pRab12, pRab29 Thr71, pRab29 Ser72, pRab29 Thr71+Ser72, pRab35 and pRab43 peptide a
loaded on Evotips as described above. The samples were analyzed in a data-dependent acquisition mode
(DDA) by disabling dynamic exclusion option on a QE HF-X instrument that is in line with the EvoSep LC
system. Full MS was acquired at 60 000 resolution (m/z) and measured in an Orbitrap mass analyzer. MS2
scans were performed by selecting top 10 precursor ions were isolated at 0.7 m/z Isolation width using segmen-
ted Quadrupole and subjected to normalized higher energy collisional dissociation of 27% (HCD) and mea-
sured using Orbitrap mass analyzer at 30 000 resolution (m/z 200). The AGC targets, 3 × 106 and 5 × 104 and
Ion filling times 20 ms and 40 ms were kept for MS1 and MS2, respectively.
LC–MS/MS analysis for total Rab peptides
For total Rab peptides samples were analyzed as above with the exception that peptides were separated on a
15 cm analytical column by employing 44 min script on EvoSep LC system [34]. The Mass spec data was
acquired in a PRM mode as explained above. The retention times of total Rab peptides were determined by
using an equimolar mixture of 50 fmol of optimized Rab1A, Rab3D, Rab8A, Rab8B, Rab10, Rab12, Rab35 and
Rab43 peptides (Supplementary Table S2)
LC–MS/MS analysis limit of detection studies
For the Limit of detection of Rab10 and Rab8A knock-out A549 cell extract and HeLa cell extract the samples
were prepared as explained above by employing 21 min run script on EvoSep LC system. Only the heavy and
light pRab10 Thr73 (FHpTITTSYYR, for z = 2 m/z 684.8028, m/z 689.8070, and z = 3 m/z 456.8710, m/z
460.2071) and only the heavy and light pRab8 Thr72 (FRpTITTAYYR for z = 2 m/z 686.3265, m/z 691.3306
and z = 3 m/z 457.8867, m/z 461.2228) with a scheduled retention times of ±4 min window was specified. The
Mass spectrometers was operated in a targeted MS2 (PRM) mode by including single Full MS and the data was
acquired as described above. MS2 scans were acquired by specifying an AGC target of 1 × 105 ions accumulated
either for 500 ms or 300 ms by applying 27% NCE of HCD and measured using Ultra high-field Orbitrap mass
analyzer at 30 000 resolution (m/z 200).
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LC–MS/MS analysis for higher-energy collisional dissociation studies
Samples were prepared as described above by employing 8 cm column and 21 min run script on EvoSep LC
system and Full MS and targeted MS2 (PRM) parameters were used except the HCD was varied at 25%, 27%
and 30% energies.
Deep proteomic profiling of wild-type MEFs studies
Forty eight bRPLC fractions were prepared for LC–MS/MS analysis by dissolving each fraction in 60 ml of 0.1%
formic acid (v/v) in 3% (v/v) acetonitrile buffer and sonicated for 10 min at room temperature. An amount of
15 ml of each fraction was analyzed on Orbitrap Exploris 480 mass spectrometer that is in-line with Dionex
3000 RSLC nano liquid chromatography system. Peptides were loaded on to 2 cm trap column (C18, 5 mm,
100 Å, 100 mm× 2 cm; PN: 164562, Thermo Scientific) and further loaded on 50 cm Easynano spray analytical
column (2 mm, 100 Å, 75 mm× 50 cm. PN: ES803, Thermo Scientific) and electro sprayed directly into the
Mass spectrometer using Easynano source. Peptides were separated by employing a gradient containing buffer
A (0.1% Formic acid (v/v) and buffer B (80% (v/v) acetonitrile in 0.1% formic acid (v/v) by employing a gradi-
ent consists of 7% B to 40% B for 70 min and further the column was kept at 90% B for 10 min and equili-
brated with 3% B for additional 20 min. The mass spectrometer was operated in a data-dependent mode in a
top speed mode for 2 s. Full MS was acquired at 60 000 resolution at m/z 200 and measured using Orbitrap
mass analyzer. The peptides were isolated by using 1.2 Da isolation width using Quadrupole mass filter and frag-
mented using 30% normalized HCD. MS/MS was acquired at 15 000 resolution at m/z 200 and measured using
Orbitrap mass analyzer. AGC target for MS was kept at 300% = 3 × 106 ions and for MS/MS 100% = 1 × 105 ions
by accumulating for a maximum of 20 ms for MS and 55 ms for MS/MS.
LC–MS/MS analysis for antibody validation
Samples were prepared as described above by employing a 15 cm column with a 44 min or 60 min run in a
DDA mode on QE-HFX mass spectrometer under the control of MaxQuant live application [35]. Full MS
was acquired at 120 000 resolution at (m/z 200) by specifying 1 × 106 AGC target and a maximum ion
injection times of 20 ms. Top 10 precursors were selected from the survey scan and were fragmented using
27% HCD and measured at 15 000 resolution (m/z 200) by specifying 1 × 105 AGC target for 28 ms ion
injection times.
Spectral library generation
Raw data was processed using Proteome Discoverer version 2.2 software and searched using Sequest algorithm
against Human/Mouse Uniprot databases (Uniprot release 2017_03) that were appended with Pierce retention
time calibration mix peptide sequences. The data was searched with a 10 ppm mass tolerance of MS1 and
0.05 Da MS2 tolerance by allowing two missed cleavages. Protease was specified as trypsin with a minimum
seven Amino acid sequence length. Oxidation of Met, deamidation of Asn/Gln, Phosphorylation of Ser/Thr,
Heavy lysine (13C6
15N2), Heavy Arginine (
13C6
15N4) were set as dynamic modifications and
Carbamidomethylation of Cys was set as fixed modifications. 1% PSM, peptide and protein FDR was applied
by validating with percolator node. Either the Proteome Discoverer result or Thermo .msf files were directly
imported into Skyline to build the spectral libraries for indicated pRabs, total Rab’s, total LRRK2 and phospho
LRRK2 and PRTC peptide sequences.
Database searches
Raw data was processed using MaxQuant (version 1.6.0.13). The data was searched against either Uniprot
(Human or Mouse 2017_03 build) using in-built Andromeda search engine. Following group specific para-
meters were used, Trypsin as a protease, Oxidation of Met, Acetyl-Protein N-terminal, Deamidation of Asn/
Gln, Phosphorylation Ser/Thr residues were selected as dynamic modifications. Carbamidomethylation of Cys
as a fixed modification. LFQ min ratio count was set to 1. Twenty parts per million of First search tolerance
and 4.5 ppm of main search tolerance was applied. 1% PSM and protein FDR was applied. MaxQuant search
output tables were processed using Perseus software suite for downstream Bioinformatic analysis. Protein
copies were estimated by using Proteomic ruler plug-in within Perseus software suite [36].
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Data analysis
The multiplexed pRabs and total LRRK2 targeted PRM assay falls into tier-2 assay as per the previously pub-
lished guidelines [37,38]. Spectral libraries were generated as described above which were used to identify and
to quantify the top six fragment ions. Mass spectrometry raw data was directly imported into Skyline software
suite (version: 19.1.0.193). The target peptides were manually entered by specifying the corresponding gene
names. Skyline software automatically picks the chromatographic traces and peak boundaries. The graphical
chromatographic traces, peak boundaries and retention time alignments for every target ion were further manu-
ally verified and further any interfering y1 or b2 ions were excluded. Samples that showed variation in Internal
standard due to the losses originated in immunoprecipitation or C18 stage-tip clean up were excluded and indi-
cated in the corresponding Supplementary Table. Synchronization of isotope label types were enabled such that
any transition that was less specific could be removed in both light and heavy labelled fragment ions. Precursor
charge states of 2,3, ion charges 1, 2 and ion types of y,b,p were selected in peptide transition settings.
Quantification was performed in determining the relative abundance was performed on both MS1 and MS2
levels. Ratio to the stable isotope internal standard values were exported into the excel sheet to determine the
relative abundance of each target peptide. The estimated phospho Rab and total LRRK2 and phospho LRRK2
abundance was calculated as described previously [39], (Light/Heavy ratio multiplied to the Spike-in amount).
The relative fold expression values were determined by Light/heavy ratio values between pathogenic LRRK2 or
VPS35[D620N] mutants versus the corresponding wild-type samples groups. For total Rab PRM analysis, peak
integration was carried out using Skyline software and extracted ion chromatograms were manually verified for
and any interfering ions of y1 or b2 ions were excluded. Light peptide intensities were exported into excel sheet
for further analysis. For Rab proteins where >1 unique peptide was monitored the summed intensities were
used. Relative levels of each Rab protein was determined by dividing the peptide intensity to the median inten-
sity of the corresponding peptide across conditions and replicates. All of the quantitation and summary of the
results are provided in Supplementary Tables S2, S3.
Bioinformatic and statistical analysis was carried out in this study using Microsoft Excel, Perseus software
suite and GraphPad prism (version 8.4.3) which includes the quantification results of both Immunoblotting
and Mass spectrometry analyzes. Finally all figures are organized in Adobe Illustrator CC version 21.1.0.
Results
Relative abundance of LRRK2 pathway components in mouse embryonic
fibroblasts
We first generated a deep proteomic profile of ∼10 000 proteins in mouse embryonic fibroblasts (MEFs) that
are widely used to study LRRK2 signalling using high resolution MS (Figure 1A,B and Supplementary
Table S2). Employing the histone-based proteomic ruler approach [40], we estimated the copy number of the
known, key LRRK2-Rab pathway components (Figure 1A,B and Supplementary Table S3). From highest to
lowest abundance we detected Rab1A and Rab10 (∼1.25 million copies per cell), Rab8A and Rab1B (∼0.65
million copies per cells), Rab8b, Rab12 and Rab35 (∼0.2 million copies per cells), Rab3A, Rab3D, Rab43 and
Rab3B (∼70 000 copies per cell), Rab29 (20 000 copies per cell). LRRK2 was lower abundance (∼6000 copies
per cell) and ranked at 7320 on our list of 10 000 most abundant proteins. Other LRRK2 pathway components
included VPS35 (∼0.7 million copies per cell), RILPL1 (∼56 000 copies per cell), RILPL2 (∼5000 copies per
cell), JIP3 (∼2000 copies per cell), JIP4 (∼0.13 million copies per cell) and PPM1H (∼10 000 copies per cells).
LRRK1 was expressed at lower levels than LRRK2 (∼3000 copies per cell).
Development of a targeted MS assay to assess LRRK2-phosphorylated Rab
proteins
As a first step towards developing a targeted MS assay to detect LRRK2-phosphorylated Rab proteins, we gener-
ated synthetic, heavy, stable isotope phospho-peptides corresponding to the tryptic peptide sequences of all
reported LRRK2 substrate Switch-II phosphorylation sites (Supplementary Table S1). These include peptides
corresponding to Rab29 phosphorylated at Thr71 or Ser72 or phosphorylated at both Thr71 and Ser72
(Supplementary Table S1). The amino acid sequences of the switch II motif peptides between each of the Rab
protein is unique, but between isoforms including Rab1 (Rab1A/B), Rab3 (Rab3A/B/C/D), Rab5 (5A/B/C) and
Rab8 (Rab8A/B) the sequences are identical and therefore cannot be distinguished (Figure 1C,D and
Supplementary Table S1). Furthermore, the monoisotopic mass of each of the pRab peptides is unique apart
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from Rab3 isoforms and Rab35 that are isobaric (Supplementary Table S1). Mixtures containing 10 or 50 fmol
of each phospho-peptide were subjected to C18 reversed-phase chromatography on an EvoSep LC system
employing a 21 min run [34]. Apart from the Rab29 peptides that elute between 1–2 min, too early to quantify,
all the other pRab peptides were well separated, allowing MS identification and quantitation of each peptide on
a QE-HFX instrument (Supplementary Figure S1A). The isobaric pRab3 and pRab35 phospho-peptides elute






Figure 1. Identification and quantification of endogenous LRRK2 signalling components in mouse embryonic fibroblasts and development
of a targeted MS assay to enrich pRab peptides.
(A) An amount of 250 mg of wild-type MEFs extract was tryptic digested, high pH fractionated and analyzed on an Orbitrap Exploris mass
spectrometer. Protein copy numbers per cell were estimated using the histone-based Proteomic ruler. The relative copy number rank is depicted in
the rank abundance plot. LRRK2-phosphorylated Rab proteins are indicated in red coloured text along with their corresponding rank number in
parentheses. Other LRRK2 signalling components are indicated in orange coloured dots and texts. (B) Relative copies of LRRK2 signalling
components depicted in bar chart, y-axis indicating the protein copies per cell for each of the indicated protein group on x-axis. (C) Endogenous
Rab substrates that are phosphorylated by LRRK2. (D) Sequence alignment of LRRK2-phosphorylated switch-II Thr and Ser Rab proteins. Rab
proteins that possess switch-II Thr phosphorylation site (Rab1, Rab3, Rab8, Rab10, Rab35 and Rab43) that are immunoprecipitates by Pan-pRab
antibody are highlighted in red coloured text. Rab29 (Thr/Ser) and Rab12 (Ser) proteins are highlighted in orange coloured text. (E) An amount of
100 fmol of equimolar heavy stable synthetic phosphoRab peptide mixture (pRab1, pRab3, pRab5, pRab8, pRab10, pRab12, pRab29 (Thr), pRab29
(Ser), pRab (Thr/Ser) and pRab43), spiked into 200 mg of bovine serum albumin tryptic digest and was subjected to peptide immunoprecipitation
using Pan-pRab antibody. Data was acquired on Orbitrap HF –X MS in a targeted PRM mode. Extracted ion chromatograms (XIC) depicting the
relative abundance of each of the Rab Phosphopeptide. X-axis indicating the retention time elution of six pRabs (Rab1, Rab3, Rab8, Rab10, Rab35,
pRab43) eluting between 7.5 to 9 min of a 21 min run on EvoSep LC-system. pRab peptides that are not immunoprecipitated by Pan-pRab antibody
(pRab29(Thr), pRab29 (Ser), pRab5 (Ser) and pRab12 (Ser) are indicated in blue-coloured text. (F). Bar graph depicting the relative abundance of
Figure E are depicted as a percentage of recovery relative to pRab10 signal. pRab peptides that are not immunoprecipitated by Pan-pRab antibody
(pRab29(Thr), pRab29 (Ser), pRab5 (Ser) and pRab12 (Ser) are indicated in blue-coloured text. n = 4, Error bars indicating the mean ± SEM.
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The retention times of the pRab peptides in independent chromatographic runs was highly reproducible in
mixtures containing 10 fmol (Supplementary Figure S1B) or 50 fmol (Supplementary Figure S1C) pRab phospho-
peptides. We compared the performance of two LC systems (the EvoSep and Dionex-RSLC3000) and found that
the signal intensity (Supplementary Figure S1D) and resolution of separation was superior on the EvoSep LC
system. In addition, the carryover of samples between independent runs using the EvoSep was below 0.1% com-
pared with 1–3% in the Dionex-RSlC3000 system (Supplementary Figure S1E). The reduced carryover of the
EvoSep system is due to utilization of a disposable tip-based trap column to load the sample. Moreover, the run
to run overhead time between runs is 2 min on the EvoSep compared with 20 min on the Dionex-RSlC3000
system allowing significantly more samples to be analyzed per day using the EvoSep LC system.
An immunoprecipitation enrichment step to isolate endogenous pRab tryptic
peptides
As discussed earlier, due to the low stoichiometry of Rab phosphorylation an enrichment step prior to MS ana-
lysis is required to robustly quantify these peptides [18,25]. Even for Rab10 that is the most abundant
LRRK2-phosphorylated Rab protein, an SDS–polyacrylamide gel electrophoresis enrichment step was found
necessary for accurate measurement of phosphorylation stoichiometry [25]. We therefore explored whether a
previously described, commercially available phospho-specific antibody termed here ‘Pan-pRab antibody’ could
be exploited to enrich pRab peptides from tryptic digests of cell extracts. Previous work had revealed that this
antibody immunoblotted and immunoprecipitated multiple endogenous Rab proteins phosphorylated on a Thr
residue by LRRK2 [7,26]. Test immunoprecipitations with an equimolar mixture of 100 fmol of the heavy
labelled pRab peptides spiked into a 200 mg tryptic digest of bovine serum albumin, revealed that the pan-pRab
antibody immunoprecipitated pRab1, pRab3, pRab8, pRab10 and pRab35 phospho-peptides quantitatively, whilst
pRab43 was also immunoprecipitated with ∼70% efficiency (Figure 1E,F). Consistent with previous work [26],
the immunoprecipitated pRab peptides all possess a Thr switch-II phosphorylation site. The pRab5, pRab12 and
pRab29 peptides possessing a Ser Switch-II motif were not immunoprecipitated (Figure 1E,F). Dose studies
revealed that 0.1 to 1 mg of pan-pRab antibody was required to immunoprecipitate pRab1, pRab3, pRab8,
pRab10 and pRab35 robustly (Supplementary Figure S1F). Even at 1 mg of pan-pRab antibody, ∼70% pRab43
was immunoprecipitated (Supplementary Figure S1F).
We next analyzed the limit of detection of this immunoprecipitation approach by spiking in pRab8 synthetic
heavy and light labelled peptides into a tryptic, 200 mg digest of an extract from Rab8A knock-out A549 cells [7]
(Figure 2A and Supplementary Figure S2A). We also spiked equivalent pRab10 peptides into extracts of Rab10
knock-out A549 cells [18] (Figure 2B and Supplementary Figure S2A). For both extracts, the heavy labelled
peptide was kept constant at 50 fmol whilst levels of the light peptide varied from 0.01 to 1000 fmol. The pRab
peptides were immunoprecipitated using the pan-pRab antibody and analyzed as above following EvoSep chro-
matography and MS analysis. This revealed that for both pRab8 and pRab10 peptides, the limit of detection for
high confidence quantitation is ∼0.1 fmol (Figure 2A,B). We detected 0.01 fmol, but quantitation was outside a
linear range. We also undertook the equivalent experiments adding synthetic heavy and light stable pRab8 and
pRab10 peptides to 50 ng of HeLa cell tryptic digest which was analyzed without an immunoprecipitation step
(Supplementary Figure S2B,C). This analysis confirmed that 0.01 fmol of pRab peptide could be detected but for
linear quantitation at least 0.1 fmol was required.
Expanding the assay to detect total and pSer910 and pSer935 phosphorylated
LRRK2
We next explored whether the PRM MS assay could be expanded to quantify total LRRK2 as well as Ser910
(UDD1) and Ser935 (UDD2) phosphorylated LRRK2. Test immunoprecipitations were performed with three
widely utilized LRRK2 total monoclonal antibodies as well as with anti-pSer910 and anti-pSer935 monoclonal
antibodies. We used 200 mg of tryptic peptide digests derived from either mouse MEFs (Supplementary
Figure S3D) or human A549 cells (Supplementary Figure S3A,D,E) that express relatively high levels of
endogenous LRRK2. MS analysis of the immunoprecipitates revealed that one of the total LRRK2 antibodies
(8G10) specifically immunoprecipitated high levels of a single tryptic peptide encompassing residues 390–401
of mouse LRRK2 (IGDEDGQFPAHQ) and the equivalent human peptide (388–399, IGDEDGHFPAHR)
(Supplementary Figure S3A). Furthermore, independent epitope mapping analysis confirmed that the 8G10
antibody detected the peptide sequence DEDGHFP (Supplementary Figure S3B). The other total LRRK2
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antibodies tested immunoprecipitated lower levels of several peptides containing missed-tryptic cleavages that
are not ideal for a targeted assay (Supplementary Figure S3A). The anti-pSer910 (UDD1) and anti-pSer935
(UDD2) monoclonal antibodies also immunoprecipitated a single LRRK2 tryptic peptide encompassing the
expected phosphorylated residues in both mouse and human cells (Supplementary Figure S3A,D,E). The pep-
tides immunoprecipitated with the 8G10 and pSer910 antibodies possess a single amino acid difference and
anti-pSer935 peptide possesses a two amino acid conservative change between the human and mouse sequences
(Supplementary Figure S3C). We therefore generated synthetic heavy stable isotope peptides encompassing the
mouse and human sequences of the tryptic peptides targeted by the 8G10, pSer910 and pSer935 LRRK2 mono-
clonal antibodies (Supplementary Table S1). These were analyzed on an EvoSep LC system in a pool in com-
bination with an equimolar amount of the pRab peptide mixture. The peptides were all well separated in a
21 min run, allowing MS identification and quantitation of each peptide.
To optimize detection we compared three different collision energies (HCD25, HCD27 and HCD30)
employing 10 fmol and 50 fmol of each peptide in 50 ng of HeLa cell tryptic peptide digest (Supplementary




Figure 2. Development of a targeted MS assay to enrich endogenous phosphorylated Rab peptides.
(A) An amount of 250 mg of Rab8A-KO A549 cell extract was subjected to tryptic digestion. Limit of detection experiments were carried out by spiking
synthetic light phosphorylated Rab8A (Thr72) peptide at (0.01, 0.1 1, 10, 50, 100, 500, 1000 fmol), while keeping the constant 50 fmol of heavy
phosphorylated Rab8A (Thr72) peptide. Immunoprecipitations were undertaken with Pan-pRab antibody and analyzed on Orbitrap HF-X MS in a
targeted PRM mode. XIC were generated using Skyline software. X-axis depicting the expected (L/H) ratio and Y-axis depicting measured (L/H) ratio.
Rectangular box indicates the zoom in of 0.01, 0.1 and 1 fmol data points. n = 3. (B) As in (A) except that 250 mg of Rab10-KO A549 cell extract was
utilized. (C–E) 1, 10 and 100 fmol of heavy synthetic six Rab peptide mixture (pRab1, pRab3, pRab8, pRab10, pRab35, pRab43) and LRRK2-pS910
and total LRRK2 peptides were spiked into 200 mg of BSA tryptic digest and sequential immunoprecipitations(IP) were undertaken using Pan-pRab
antibody. Levels of peptides eluted from the beads on the first round (IP-1) and second round IP (IP-2) are indicated. Samples were analyzed in a PRM
mode. Data was analyzed to assess the relative recovery of pRabs in each round of IP, N = 3, error bars indicating the mean ± SEM.
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observed to provide the optimal collision energy to assess this set of peptides. It should be noted that Rab43
had the highest variation (∼12%) while the Rab peptides displayed a median coefficient of variation of 4.5%
(Supplementary Figure S4A–D). All subsequent analysis undertaken in this study was therefore performed at
HCD27.
Multiplexing of pan-pRab, 8G10, pSer910 and pSer935 antibodies
We next multiplexed the pan-pRab, 8G10, pSer910, pSer935 and antibodies (0.5 mg each) to verify whether
these could efficiently immunoprecipitate the pRab peptides using mouse (Figure 2C–E) or human
(Supplementary Figure S2D–F) peptides. Test immunoprecipitations were undertaken with an equimolar
mixture of 1 fmol (Figure 2C and Supplementary Figure S2D), 10 fmol (Figure 2D and Supplementary
Figure S2E) and 100 fmol (Figure 2E and Supplementary Figure S2F) of each of the peptides spiked into a
200 mg tryptic digest of bovine serum albumin. To maximize recovery of Rab43, we compared recovery of each
peptide after two rounds of immunoprecipitation. This analysis revealed that all peptides in the 1–100 fmol
tested conditions, including Rab43, were efficiently immunoprecipitated by >95% after two rounds of immuno-
precipitation; we could also readily detect and quantify mouse (Figure 2C–E) and human (Supplementary
Figure S2D–F) peptides.
Quantitation of total Rab proteins in cell extracts
As Rab proteins are much more abundant than LRRK2 (Figure 1A,B), we next explored whether we could dir-
ectly detect and quantify signature tryptic peptides derived from individual Rab proteins straight in tryptic
digests of 500 ng of wild-type MEFs analyzed using the EvoSep LC system on the QE-HFX instrument. Using
a 44 min run, we reliably detected tryptic peptides derived from Rab1A, Rab1B, Rab3D, Rab8A, Rab8B, Rab10,
Rab12, Rab35 and Rab43 at a high signal to noise range; Rab29 and LRRK2 that are expressed at low levels
(Figure 1A,B) were below the detection limit. In a 21 min run, levels of Rab8B, Rab35 and Rab43 that are less
abundant than the other Rabs (Figure 1A,B), were harder to detect and quantify reliably. We therefore adopted
the 44 min run protocol. For each Rab protein, we selected between 1 and 3 unique proteotypic peptides of the
same sequence in mouse and human that based on our proteome analysis, permits robust detection and quan-
titation of Rab1A, Rab1B, Rab3D, Rab8A, Rab8B, Rab10, Rab12, Rab35 and Rab43 proteins. The sequence and
m/z of these peptides are listed in Supplementary Table S1. We synthesized heavy stable isotope peptides for
each of these Rab proteins and spiked 50 fmol (Supplementary Figure S5A) or 10 fmol (Supplementary
Figure S5B) of these peptide mixtures into 50 ng of Hela tryptic digest. These peptides separate well on a
45 min EvoSep run, allowing quantitation of Rab proteins in the tryptic digest without further enrichment
(Supplementary Figure S5A).
Workflow to quantify phosphorylated and total LRRK2 and Rab proteins in cell
and tissue extracts
Based on the groundwork described above, we developed a workflow to assess endogenous levels of total and
LRRK2-phosphorylated Rab1, Rab3, Rab8, Rab10, Rab35 and Rab43 as well as total LRRK2 and
LRRK2-phosphorylated Ser910 and Ser935 (Figure 3). In this workflow, cells or tissues are lysed with conven-
tional lysis buffer containing detergents such as 1% (v/v) Triton-X100 required to solubilize Rab proteins in
addition to phosphatase inhibitors. For MEFs, mouse liver, kidney and spleen extracts that express relatively
high levels of LRRK2, we typically used 0.15–0.3 mg per sample. For mouse brain that expresses lower levels of
LRRK2, we used 1 mg extract per sample.
The cell/tissue extract is reduced, alkylated and absorbed onto an to S-Trap (suspension trap) spin column [41],
which is washed to remove detergents and non-protein debris. Tryptic digestion is performed on the S-Trap
column, peptides are eluted and accurately quantified using the fluorescence-based CBQCA method [33]. For total
Rab protein analysis, 0.5 mg of tryptic digest (<0.5% of the total peptides) is spiked with 50 fmol of synthetic
heavy labelled isotope Rab1A, Rab1B, Rab3D, Rab8A, Rab8B, Rab10, Rab12, Rab35 and Rab43 markers. Total
Rab protein levels are quantified using a 44 min EvoSep LC run and data analyzed as described above. For the
immunoprecipitation enrichment step, 150 mg (MEF, neutrophil, mouse lung, kidney, spleen) or 650 mg (mouse
brain) derived tryptic peptide digest is spiked with 100 fmol cocktail of pRab1, pRab3, pRab8, pRab10, pRab35,
pRab43, LRRK2(388–399), p910 LRRK2, and p935LRRK2 standard heavy labelled peptides. Immunoprecipitations
with a mixture of the pan-pRab, 8G10, p910 and p935 antibodies are undertaken. To maximize recovery of
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pRab43 two rounds of immunoprecipitation are performed. The data is analyzed to quantify the total and phos-
phorylated levels of pRab1, pRab3, pRab8, pRab10, pRab35 and pRab43 as well as total LRRK2, pSer910-LRRK2
and pSer935-LRRK2.
Targeted analysis of the LRRK2-Rab pathway in wild-type and VPS35[D620N]
MEFs
To verify whether our assay can reliably quantify endogenous phosphorylated and total LRRK2 and Rab pro-
teins, we treated littermate-matched, primary wild-type and VPS35[D620N] knock-in MEFs with increasing
doses of MLi-2 LRRK2 inhibitor and analyzed samples at each dose in triplicate [42]. Cell extracts were pre-
pared and analyzed either by the targeted MS assay workflow (Figure 4) or by conventional immunoblotting
(Figure 5B). Using the targeted MS assay, we were able to quantify all the pRab, total-Rab, total-LRRK2
pSer910/pSer935-LRRK2 endogenous peptides above the linear detection limit (Figure 4). The MS data is pre-
sented as fmol peptide/mg of tryptic peptide digest. Total Rab peptides are presented relative to the median
intensity of each corresponding Rab peptide (Figure 4). We also analyze the relative fold change between wild-
type and VPS35[D620N] (Figure 4) and the relative fold change ± 100 nM MLi-2 (Figure 4). MLi-2 IC50 curves
for each pRab as well as pSer910/pSer935-LRRK2 are presented in (Supplementary Figure S6A–H). The data
reveal a 5.5-fold increase in pRab10 levels in the VPS35[D620N] compared with wild-type MEFs (Figures 4D, 5B).
MS analysis demonstrates that MLi-2 reduced pRab10 levels with an IC50 of ∼3 nM (Figure 4D and
Supplementary Figure S6D). The VPS35[D620N] mutation increased phosphorylation levels of pRab1 (3.1-fold
Figure 4A), pRab3 (2-fold Figure 4B), pRab8 (6.2-fold Figure 4C), pRab10 (5.5-fold, Figure 4D), pRab35 (3.3-fold
Figure 4E) and pRab43 (5.3-fold Figure 4F). The IC50 values for inhibition by MLi-2 were 2–3 nM for all of the
pRab proteins (Supplementary Figure S7A–F). Immunoblotting analysis of the same samples used in the MS ana-
lysis confirmed that pRab10 levels were increased ∼6-fold in the VPS35[D620N] knock-in cells and reduced to
basal levels in a dose-dependent manner by MLi-2 treatment with an IC50 of ∼3 nM, consistent with previous
analysis [15] (Figure 5B).
Figure 3. Workflow of targeted LRRK2-Rab pathway assay.
Summary of workflow we have developed to quantify endogenous levels of pRab, total Rab, LRRK2-pS910/pS935 and total
LRRK2 peptides in cells and tissue extracts.
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Figure 4. Targeted MS analysis of LRRK2-Rab signalling pathway in wild-type and VPS35[D620N] MEFs. Part 1 of 2
Littermate matched wild-type and homozygous VPS35 [D620N] MEFs were treated with the indicated concentrations of MLi-2 for 90 min prior to
harvest and subjected to either tryptic digestion (A–I) or immunoblot analysis (Figure 5B). (A–I) An amount of 150 mg of digest was spiked with an
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A high dose of 100 nM MLi-2 reduced pRab10 levels 21-fold in wild-type and 75-fold in VPS35[D620N]
MEFs (Figure 4D). For wild-type cells, pRab43 phosphorylation was reduced over 10-fold by 100 nM MLi-2,
with other pRabs impacted between 1.3 to 4-fold (Figure 4). The impact of 100 nM MLi-2 was much greater in
VPS35[D620N] knock-in cells displaying higher levels of pRabs. For pRab8, pRab10, pRab35 and pRab43 the
effects were over 10-fold, but lower for pRab1 and pRab3 (Figure 4). The relative abundance of the different
pRab are shown in Table 1. Ranking abundance of pRabs from high to low in VPS35[D620N] MEFs are
pRab10, pRab1, pRab8, pRab35, pRab43 and pRab3. Consistent with previous results the total levels of Rab
proteins were similar in wild-type and VPS35[D620N] MEFs (Figure 4).
As outlined in the Introduction, in previous work we had not observed an increase in endogenous pRab1
phosphorylation in LRRK2 pathogenic knock-in MEFs treated ± LRRK2 inhibitors [7]. To obtain further evi-
dence that the VPS35[D620N] mutation increased pRab1 levels, we performed additional immunoblotting of
wild-type and VPS35[D620N] extracts immunoprecipitated with the pan-pRab antibody. This confirmed that
∼3-fold increased levels of Rab1 were immunoprecipitated from VPS35[D620N] compared with wild-type cells
(Figure 5A). Treatment of VPS35[D620N] cells with MLi-2 reduced pRab1 levels to levels observed in wild-type
cells (Figure 5A). As observed previously [7], and consistent with our MS analysis (Figure 4), MLi-2 did not
lower levels of pRab1 in wild-type cells (Figure 5A).
MLi-2 also reduced Ser910 and Ser935 phosphorylation in a dose-dependent manner, with an IC50 of
∼3 nM in both wild-type and VPS35 [D260N] MEFs (Figures 4G,H, 5B). Levels of LRRK2 and pSer910 and
pSer935 were identical in wild-type and VPS35[D620N] MEFs and not altered by the 90 min MLi-2 treatment
(Figure 4G–H), consistent with previous data [15]. These findings are also consistent with immunoblot analysis
undertaken in parallel (Figure 5B).
Validation of targeted MS assay using MLi-2 resistant LRRK2[A2016T] MEFs
We previously described a mutation (A2016T) within the LRRK2 kinase domain of LRRK2 that does not affect
basal kinase activity but renders LRRK2 ∼10-fold resistant to several kinase inhibitors including MLi-2 [8,43].
To further validate the targeted-MS assay, we treated littermate-matched, wild-type and LRRK2[A2016T]
knock-in MEFs [8] with increasing doses of MLi-2 and used targeted MS to calculate abundances of total and
phospho Rab proteins as well as total and pSer910/pSer935-LRRK2 (Figure 6); IC50 values were also calculated
(Supplementary Figure S8A–H). For pRab10, pRab8, pRab43, pSer910-LRRK2, pSer935-LRRK2, the A2016T
mutation increased IC50 values from 3 nM to 30–40 nM MLi-2 (Supplementary Figures S8A–C,G–H). MLi-2
had no significant effect on the levels of pRab1, pRab3 or pRab35 in A2016T MEFS (Supplementary
Figure S7A–C). The total levels of Rab and LRRK2 were similar in the wild-type and LRRK2 [A2016T]
knock-in MEFs (Figure 6A–C and Supplementary Figure S7A–F). Similar results were obtained in parallel by
immunoblotting (Supplementary Figure S9A,B).
Further validation of targeted MS assay using LRRK2[R1441C] pathogenic
MEFs
We next compared abundance of total and phospho Rab proteins as well as total and pSer910/pSer935-LRRK2
levels in littermate-matched wild-type and LRRK2[R1441C] pathogenic mutant MEFs treated ± 100 nM MLi-2
using the targeted MS assay (Figure 7). This revealed significantly increased levels of pRab8 (2.7-fold), pRab10
(2.5-fold), pRab35 (2.6-fold) and pRab43 (3.5-fold) in the LRRK2[R1441C] knock-in MEFs compared with
wild-type. MLi-2 treatment markedly reduced pRab and pSer910/pSer935-LRRK2 levels (Figure 7A). The
LRRK2 [R1441C] mutation had little impact on pRab1 or pRab3 levels (Figure 7B). Previous studies have
Figure 4. Targeted MS analysis of LRRK2-Rab signalling pathway in wild-type and VPS35[D620N] MEFs. Part 2 of 2
equimolar ratio of 100 fmol heavy pRabs and LRRK2 pS910/pS935 and total LRRK2 peptides and subjected to sequential immunoprecipitation (IP)
with a multiplexed antibody cocktail (Pan-pRab, UDD1, UDD2 and 8G10) and peptide levels quantified as fmol peptide/mg of tryptic digest (upper
panel). In parallel, 0.5 mg of tryptic digest spiked with an equimolar ratio of 50 fmol of heavy total Rab peptides and data was acquired in PRM
mode and peptide levels normalzsed to the median peptide intensity (lower panel). Dotted arrows indicate the differences between the indicated
samples and one tailed or two tailed student t-test was performed to depict the significance of change indicated with *. Three independent replicate
experiments were performed for each of the indicated MLi-2 concentration and each dot indicates values for each experiment. P values for DMSO
versus MLi-2 and WT versus VPS35[D620N] are provided in Supplementary Table (Supplementary Table S2). Error bars representing mean ± SEM.
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Figure 5. Enhanced LRRK2-mediated Rab1 phosphorylation in homozygous VPS35 [D620N] knock-in MEFs. Part 1 of 2
Littermate matched wild-type and homozygous VPS35[D620N] knock-in mouse embryonic fibroblasts were treated ±200 nM MLi-2 for 2 h prior to
lysis. Immunoprecipitation using the Pan-pRab antibody was performed on 2 mg of whole cell extract and immunoprecipitates were subjected to
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Figure 5. Enhanced LRRK2-mediated Rab1 phosphorylation in homozygous VPS35 [D620N] knock-in MEFs. Part 2 of 2
Rab1-Total (80% of sample) and Rab10-Total (20% of sample) immunoblotting, with 15 mg of whole cell extract used for input (A). Each lane
represents cell extracts obtained from a different dish of cells (two replicates per condition). Immunoblots were subjected to quantitative LI-COR
immunoblot analysis with all indicated antibodies at 1 mg/ml, except VPS35 and Tubulin antibodies at 0.1 mg/ml. Bar graphs depicting a significant
2.7 fold elevation of pRab1 in VPS35[D620N] MEFs was observed relative to the wild-type MEFs in Pan-pRab immunoprecipitation similarly a 7.9
fold increase in pRab10 was observed in VPS35[D620N] MEFs. Bar graphs depicting an increase in pRab10 (5.5) fold and LRRK2-pS935 in VPS35
[D620N] MEFs input (B) The indicated WT and VPS35[D620N] MEFs generated in Figure 4, were treated with or without the indicated
concentrations of MLi-2 for 90 min. Cells were lysed, and 10 mg of extract was subjected to quantitative immunoblot analysis with the indicated
antibodies (all at 1 mg/ml). Each lane represents cell extract obtained from a different dish of cells (3–4 replicates per condition). The membranes
were developed using the Odyssey CLx Western Blot imaging system. Immunoblots were quantified using the Image Studio software. Data are
presented relative to the phosphorylation ratio observed in WT cells treated with DMSO (no inhibitor), as mean ± SEM. Statistical significance for
pRab10 between VPS35-D620N and WT untreated cells is determined by one tailed t-test (P = <0.00001). n= 3, error bars representing the mean±SEM.
Table 1 Summary of pRabs (pRab1, pRab3, pRab8, pRab10, pRab35 and pRab43), LRRK2-pS910, LRRK2-pS935 and
total LRRK2 relative abundance in Wt MEFs, LRRK2 R1441C MEFs, VPS35[D620N] MEFs, Human Neutrophils, Wt,
LRRK2 R1441C and VPS35[D620N] mice whole brain, lungs, spleen and kidney
Sample
Estimated relative abundance of pRabs and LRRK2-pS910, pS935 and total LRRK2 (fmol/mg)













9.9 (0.7) 45.5 (4.6) 53.0 (4.5) 70.6
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Whole brain — Wt (−MLi2)
(+MLi2)
1.5 (2.1) 3.6 (3.9) 0.8 (1.6) 4.2 (3.9) 3.9 (1.9) 0.4 (0.3) 10.3 (2.6) 23.3 (1.2) 24.4
(20.8)
Whole brain — LRRK2
R1441C (−MLi2)
3.2 (3.0) 9.0 (6.3) 2.0 (1.8) 14.7 (8.1) 4.1 (2.8) 1.6 (0.4) 3.5 (1.5) 6.3 (2.1) 45.2
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[D620N] (MLi2) (+MLi2)
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(27.5)
Kidney- Wt (−MLi2) (+MLi2) 3.6 (3.8) 20.4
(10.5)
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shown that the LRRK2[R1441C] mutation reduces phosphorylation of LRRK2 at Ser910 and Ser935 [22].
Consistent with this, the targeted MS assay revealed a 2-fold reduction in the phosphorylation of Ser910 and
Ser935 phosphorylation sites in the R1441C MEFs compared with wild-type (Figure 7A,B). Similar results were
also observed in parallel immunoblotting results for pRab10 and pSer935-LRRK2 (Figure 7C,D).
LRRK2-Rab targeted MS assay on wild-type and LRRK2[R1441C] mouse
tissues
We next evaluated whether the targeted MS assay could be deployed to assess the LRRK2-Rab pathway in
tissues extracts derived from littermate wild-type and LRRK2[R1441C] knock-in mice (Figure 8). For these
studies we analyzed six mice per group, two of which were treated by sub-cutaneous injection of 30 mg/kg
MLi-2 for 2 h prior to tissue harvesting. We undertook tissue analysis from kidney and whole brain, lung and
A B C
D E F
Figure 6. Targeted MS assay of LRRK2-Rab signalling pathway in wild-type and LRRK2-A2016T MEFs.
Littermate matched wild-type and homozygous LRRK2[A2016T] MEFs were treated with the indicated concentrations of MLi-2 for 90 min prior to
harvest and subjected to either tryptic digestion (A–F) or immunoblot analysis (Supplementary Figure S9A,B). (A–F) 150 mg of digest was spiked with
an equimolar ratio of 100 fmol heavy pRabs and LRRK2 pS910/pS935 and total LRRK2 peptides and subjected to sequential immunoprecipitation (IP)
with a multiplexed antibody cocktail (Pan-pRab, UDD1, UDD2 and 8G10) and peptide levels quantified as fmol peptide/mg of tryptic digest (upper
panel). In parallel, 0.5 mg of tryptic digest spiked with an equimolar ratio of 50 fmol of heavy total Rab peptides and data was acquired in PRM mode
and peptide levels normalized to the median peptide intensity (lower panel). Dotted arrows indicated the differences between the indicated samples
and one tailed or two tailed student t-test was performed to depict the significance of change indicated with *. Three independent replicate
experiments were performed for each of the indicated MLi-2 concentration and each dot indicates values for each experiment. Error bars representing
mean ± SEM. Data for pRab1, pRab3, pRab35 that not change significantly with MLi-2 is presented in Supplementary Figure S7A–F.
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spleen (Figure 8) in which the LRRK2 signalling pathway has been investigated previously [21]. For lung,
kidney and spleen, 150 mg of tryptic peptide digest was used and was sufficient to detect robustly all pRabs and
total-LRRK2 and pSer910/pSer935-LRRK2. For the brain, pRab levels were ∼4-fold lower, and we therefore uti-
lized 600 mg of tryptic peptide digest derived from 1 mg cell extract. The relative abundance of each pRab
protein in every tissue ±MLi-2 is shown in Figure 8 and Table 1. The LRRK2[R1441C] mutation moderately
increased Rab10 phosphorylation in brain (1.5-fold), lung (1.7-fold), kidney (1.7-fold) and spleen (1.5-fold). In
the brain, the LRRK2[R1441C] mutation also increased Rab43 phosphorylation 3-fold. In lung, kidney and




Figure 7. Targeted MS assay of LRRK2-Rab signalling pathway in wild-type and LRRK2-R1441C MEFs.
Littermate matched wild-type and homozygous LRRK2[R1441C] MEFs were treated ±100 nM MLi-2 for 90 min prior to harvest and subjected to
either tryptic digestion (A,B) or immunoblot analysis (C). (A) An amount of 150 mg of digest was spiked with an equimolar ratio of 100 fmol heavy
pRabs and LRRK2 pS910/pS935 and total LRRK2 peptides and subjected to sequential immunoprecipitation (IP) with a multiplexed antibody
cocktail (Pan-pRab, UDD1, UDD2 and 8G10) and peptide levels quantified as fmol peptide/mg of tryptic digest (upper panel). In parallel, 0.5 mg of
tryptic digest spiked with an equimolar ratio of 50 fmol of heavy total Rab peptides and data was acquired in PRM mode and peptide levels
normalized to the median peptide intensity (lower panel). Dotted arrows indicated the differences between the indicated WT and R1441c samples
and two tailed student t-test was performed to depict the significance of change indicated with *. Four independent replicate experiments were
performed for each of the indicated MLi-2 concentration and each dot indicates values for each experiment. P values for WT versus LRRK2[R1441C]
are provided in Supplementary Table S2. Error bars representing mean ± SEM. (B) Bar chart indicating the relative fold change between levels of
indicated peptides between LRRK2[R1441C] versus wild-type ± SEM. (C) An amount of 10 mg of extract was subjected to quantitative immunoblot
analysis with the indicated antibodies (all at 1 mg/ml). Each lane represents cell extract obtained from a different dish of cells (3–4 replicates per
condition). The membranes were developed using the Odyssey CLx Western Blot imaging system. Immunoblots were quantified using the Image
Studio software. (D) Data are presented relative to the phosphorylation ratio observed in WT cells treated with DMSO (no inhibitor), as mean ± SEM.
One tailed student t-test representing the statistical significance of pRab10 and LRRK2-pS935 between LRRK2 R1441C and WT MEFs. Significance
representing for the immunoblot analysis of pRab10 (P = 0.000036), LRRK2-pS935 (<0.00001). Error bars indicating the mean ± SEM.
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Figure 8. Targeted MS assay of LRRK2-Rab signalling pathway in WT and LRRK2[R1441C] mouse tissues. Part 1 of 2
(A–D) Wild-type and homozygous LRRK2 R1441C litter mate matched six months old mice were administered with vehicle (40% (w/v)
(2-hydroxypropyl)-β-cyclodextrin) or 30 mg/kg MLi-2 dissolved in vehicle was injected sub-cutaneous 2 h prior to the tissue collection. Tissues were
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administration significantly reduced these pRabs to lower levels similar to levels observed in wild-type mice
treated with MLi-2 (Figure 8, Table 1). Consistent with previous work [22], levels of Ser910 and Ser935 phos-
phorylated LRRK2 were reduced 4 to 5-fold in all tissues from LRRK2[R1441C] animals compared with wild-
type. Similar results were also observed in parallel immunoblotting results for pRab10 and pSer935-LRRK2
(Supplementary Figure S10A,B).
Use of the LRRK2-Rab targeted MS assay on wild-type and VPS35[D620N]
knock-in mouse tissues
We further analyzed LRRK2 pathway components in brain, lung, kidney and spleen from littermate-matched
wild-type and VPS35[D620N] mice, also using six animals in each group (four untreated and two treated with
30 mg/kg MLi-2 for 2 h). VPS35[D620N] mutation enhanced pRab protein phosphorylation to a greater extent
than observed with the R1441C mutation (compare Figures 7, 8). In brain, the VPS35[D620N] enhanced
pRab10 (1.8-fold), pRab8 (1.6-fold), Rab43 (3-fold) with no change observed for pRab1, pRab3 and pRab35
(1.4-fold). In other tissues, the VPS35[D620N] mutation increased pRab10, pRab8, Rab43 and pRab35 1.3–
3.1-fold (Figure 9). As in MEFs, the D620N mutation enhanced pRab1 phosphorylation 1.3–1.9-fold in lung,
kidney and spleen. MLi-2 reduced levels of pRab8, pRab10, pRab35 and pRab43 as well as pRab1 in VPS35
[D620N] MEFs, 2 to 10-fold without impacting pRab3. Levels of Ser910 and Ser935 phosphorylated LRRK2
were similar in wild-type and VPS35[D620N] tissues. Analogous results were also observed in parallel
immunoblotting results for pRab10 and pSer935-LRRK2 (Supplementary Figure S11A,B).
Use of the LRRK2-Rab PRM MS assay on human primary neutrophils
In clinical studies, the LRRK2 pathway has been evaluated in primary neutrophils as these cells express high
levels of LRRK2 and can be easily isolated from donors and patients [15,30,31]. To first evaluate the utility of
the targeted MS assay, neutrophils were isolated from three healthy donors and cells treated with increasing
concentrations of MLi-2 prior to lysis. Similar to previous observations [25,30], immunoblotting analysis
revealed that MLi-2 markedly reduced pRab10 levels at 100–300 nM with little inhibition observed at lower
concentrations (Supplementary Figure S12). Similar results were observed for pRab10 andpSer910/
pSer935-LRRK2 (Supplementary Figure S12). MLi-2 (100 or 300 nM) reduced pRab10, pRab43, pSer910 and
pSer935 by over 80%. In contrast, pRab1, pRab3, pRab8 and pRab35 were not reduced by MLi-2 administra-
tion. We observed some variation in pRab levels between donors. For example, donor-2 displayed moderately
higher total LRRK2, pRab10 and pSer910/pSer935-LRRK2 (Supplementary Figure S12). Similar results were
also observed in parallel immunoblotting results for pRab10 and pSer935-LRRK2 (Supplementary
Figure S12E).
Finally, we obtained neutrophils form three Parkinson’s patients with VPS35[D620N] mutations and three
healthy control donors (Figure 10). Previous work by immunoblot [15] and MS analysis [25], indicated that
neutrophils isolated from VPS35[D620N] subjects displayed 2 to 4-fold elevation in pRab10 levels. Consistent
with previous work, our targeted MS assay reveals 2 to 5.4-fold elevation in pRab10 levels in the three sets of
neutrophils analyzed compared with controls (Figure 10A). Interestingly, pRab43 (Figure 10B) and pRab8
(Figure 10C) were also elevated up to 6-fold in VPS35[D620N] subjects. We also noted a moderate ∼1.5-fold
elevation of pRab1 (Figure 10D) and pRab3 (Figure 10E) in the VPS35[D620N] subjects. In contrast, levels of
pRab35 were barely increased in the VPS35[D620N] neutrophils (Figure 10F). Immunoblot analysis
(Figure 10J) of these samples reveals strong correlation with MS analysis between the subjects. The subjects
display the equivalent degree of elevated pRab10 levels in both assays (compare Figure 10A with Figure 10J).
Figure 8. Targeted MS assay of LRRK2-Rab signalling pathway in WT and LRRK2[R1441C] mouse tissues. Part 2 of 2
harvested and subjected to either tryptic digestion (A–D) or immunoblot analysis (Supplementary Figure S10A,B). (A–D) Either 600 mg (brain) or
150 mg (lung, kidney, spleen) tryptic digest was spiked with an equimolar ratio of 100 fmol heavy pRabs and LRRK2 pS910/pS935 and total LRRK2
peptides and subjected to sequential immunoprecipitation (IP) with a multiplexed antibody cocktail (Pan-pRab, UDD1, UDD2 and 8G10) and
peptide levels quantified as fmol peptide/mg of tryptic digest (upper panel). In parallel, 0.5 mg of tryptic digest spiked with an equimolar ratio of
50 fmol of heavy total Rab peptides and data was acquired in PRM mode and peptide levels normalized to the median peptide intensity (lower
panel). Two to four independent replicate experiments were performed for each of the indicated conditions and each dot indicates values for each
experiment. Error bars representing mean ± SEM.
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Figure 9. Targeted MS assay of LRRK2-Rab signalling pathway in WT and VPS35[D620N] mouse tissues. Part 1 of 2
(A–D) Wild-type and homozygous VPS35[D620N] litter mate matched six months old mice were administered with vehicle (40% (w/v)
(2-hydroxypropyl)-β-cyclodextrin) or 30 mg/kg MLi-2 dissolved in vehicle was injected sub-cutaneous 2 h prior to the tissue collection. Tissues were
harvested and subjected to either tryptic digestion (A–D) or immunoblot analysis (Supplementary Figure S11A,B). (A–D) Either 650 mg (brain) or
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Discussion
The LRRK2-Rab targeted MS assay described here requires a hybrid quadrupole Orbitrap mass spectrometry
instrument and preferably an EvoSep liquid chromatography system. The key antibodies (Pan-pRab, 8G10,
UDD1 and UDD2) used for the peptide enrichment immunoprecipitation step are commercially available and
the series of heavy labelled, stable synthetic peptides (Supplementary Table S1) required for accurate identifica-
tion and quantification can be easily obtained. For cells and tissues that express relatively high levels of LRRK2
(MEFs, mouse lung, kidney, spleen and human neutrophils), 150 mg of tryptic peptide digest that can readily
be obtained from 0.2–0.25 mg of cell/tissue extract is sufficient for analysis. For neutrophil samples derived
from Parkinson’s patients for which sample volume was limiting we used 100 mg of cell extract and 60 mg of
tryptic peptide digest. For brain samples where levels of LRRK2 are expressed at lower levels, we utilized 600–
650 mg of tryptic peptide digest that can be obtained from 0.8 to 1 mg of brain extract. In all cells and tissue
extracts analyzed, we detected and quantified six LRRK2-phosphorylated pRab proteins (pRab1, pRab3, pRab8,
pRab10, pRab35, pRab43) as well as the total Rab, total LRRK2 and pSer910/pSer935 peptides. The levels of
these components are comfortably above the assay linear limit of detection. We present the abundance levels of
these peptides as fmol detected peptide/mg of tryptic peptide digest that permits the relative levels of pRab pro-
teins to be compared between different tissues and cells (Table 1).
The S-Trap on column digestion workflow allows for a simplified tryptic peptide digest preparation without
requiring an additional desalting step. The tryptic digestion and immunoprecipitation steps could be automated
using liquid handling platforms to increase throughput of the assay in a 96 well plate format. Sample prepar-
ation to the MS requires 2 days (1 day for peptide digest and 1 day for immunoprecipitation and sample clean
up). To prepare 24 samples for tryptic peptide digest requires ∼8 h on day 1 (2 h reduction and alkylation, 2 h
S-Trap loading and clean up, 2 h tryptic digestion, 2 h peptide quantitation) followed over overnight lyophiliza-
tion. Day 2 requires 9 h (2 × 2 h antibody incubation, 2 h washing immunoprecipitates, 2 h desalting samples
and 1 h vacuum drying). Samples at this stage can be stored at −80°C or directly loaded on the Evotips (2 h for
24 samples) and then stored at 4°C for up to 1 week prior to MS analysis. For the total Rab samples, aliquots
of the tryptic peptides are directly loaded on the Evotips. The MS instrument time required to analyze the
pRabs, pSer910/pSer935 and total LRRK2 is 21 min, enabling ∼60 samples to be processed per day. The total
Rab samples require a longer 45 min gradient, allowing ∼30 samples per day to be analyzed. If both pRabs and
total Rab peptides are evaluated in parallel, ∼20 sets of samples can be analyzed per day. We find that the
levels of total Rabs are constant between cell lines and tissues, and if dose-dependence curves and time courses
are being undertaken, it may not be necessary to monitor total levels of Rab protein for every dose or
time point.
One of the key limitations of our targeted MS assay is that it does not detect pRab12, as this peptide is not
immunoprecipitated with the Pan-pRab antibody (Supplementary Figure S5D,E). pRab12 levels are especially
high in brain and are more impacted than Rab10 by LRRK2 mutations and inhibitors in that tissue [21,44].
Only a single pRab12 phospho-specific monoclonal antibody is commercially available and we have found that
this does not immunoprecipitate pRab12 peptide (Supplementary Figure S5D,E). In future work, it would be
important to raise an immunoprecipitating pRab12 antibody to enable pRab12 levels to be quantified. Our
studies are consistent with previous work [21,44], that in wild-type brain, pRab levels including Rab10 are
lower compared with other tissues and cells analyzed and MLi-2 administration has little impact on any of the
impact on the phosphorylation levels of any other Rab protein studied (Figures 8A, 9A).
In Table 1 we summarize our data on the relative levels of pRab proteins in MEFs, human neutrophils,
mouse brain, lung, kidney and spleen. In MEFs, neutrophils, and lung, pRab10 is abundant. In the kidney and
Figure 9. Targeted MS assay of LRRK2-Rab signalling pathway in WT and VPS35[D620N] mouse tissues. Part 2 of 2
150 mg (lung, kidney, spleen) tryptic digest was spiked with an equimolar ratio of 100 fmol heavy pRabs and LRRK2 pS910/
pS935 and total LRRK2 peptides and subjected to sequential immunoprecipitation (IP) with a multiplexed antibody cocktail
(Pan-pRab, UDD1, UDD2 and 8G10) and peptide levels quantified as fmol peptide/mg of tryptic digest (upper panel). In
parallel, 0.5 mg of tryptic digest spiked with an equimolar ratio of 50 fmol of heavy total Rab peptides and data was acquired in
PRM mode and peptide levels normalized to the median peptide intensity (lower panel). Two to four independent replicate
experiments were performed for each of the indicated conditions and each dot indicates values for each experiment. Error bars
representing mean ± SEM.
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).322
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spleen, levels of pRab3 and pRab43, respectively, are moderately higher than pRab10. The fold-impact of
MLi-2 is greatest for the pRabs whose phosphorylation is most enhanced by the LRRK2[R1441C] or VPS35
[D620N] mutation. We observed that the VPS35[D620N] mutation in MEFs, as well as lung and kidney,
increased pRab1 phosphorylation 1.6 to 3.5-fold in a manner that was suppressed by MLi-2. In MEFs we con-
firmed this result by immunoblotting analysis (Figure 5A). Consistent with previous work [7], pRab1 levels are
relatively high in wild-type cells and tissues, but not elevated further in LRRK2[R1441C] pathogenic samples
or lowered following treatment with MLi-2 (Table 1). Rab1 is reportedly phosphorylated by TAK1 kinase at
this LRRK2 site (Thr75) [45]. As the phosphorylation of Rab1 at Thr75 is not impacted by LRRK2 inhibitors
or LRRK2[R1441C] mutation, it is unlikely that TAK1 or other Thr75 protein kinase(s) phosphorylating Rab 1
in non-VPS35[D620N] mutant cells, are regulated by LRRK2. Future work is required to uncover the mechan-
ism by which the VPS35[D620N] mutation promotes LRRK2-mediated Rab1 phosphorylation as well as other
A B C G H I
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Figure 10. Targeted MS analysis of LRRK2-Rab signalling pathway in healthy donors and VPS35 [D620N] patients neutrophils.
(A–I) An amount of 60 mg of tryptic digest as technical duplicates from 3 healthy donors and 3 VPS35 [D620N] patient samples that are treated with
±MLi-2 was spiked with an equimolar ratio of 100 fmol heavy pRabs and LRRK2 pS910/pS935 and total LRRK2 peptides and subjected to
sequential immunoprecipitation (IP) with a multiplexed antibody cocktail (Pan-pRab, UDD1, UDD2 and 8G10) and peptide levels quantified as fmol
peptide/mg of tryptic digest (upper panel). In parallel, 0.5 mg of tryptic digest spiked with an equimolar ratio of 50 fmol of heavy total Rab peptides
and data was acquired in PRM mode and peptide levels normalized to the median peptide intensity (lower panel). Dotted arrows indicate the
differences between the indicated samples and one tailed or two tailed student t-test was performed to depict the significance of change indicated
with *. Three independent replicate experiments were performed for each of the indicated MLi-2 concentration and each dot indicates values for
each experiment. Error bars representing mean ± SEM. (J) 10 mg of extract was subjected to quantitative immunoblot analysis with the indicated
antibodies (all at 1 mg/ml). Each lane represents cell extract obtained from a different donors colour coded (Donor1 = blue, Donor2 = red and Donor3
= green). Data are presented relative to the phosphorylation ratio observed in cells treated with DMSO (no inhibitor), as mean ± SEM. Statistical
analysis was performed by two tailed student t-test indicating the significance between VPS35 [D20N] and healthy donors.
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Rab substrates. Our data with a small number of neutrophils isolated from VPS35[D620N] Parkinson’s patients
demonstrates a modest ∼1.5-fold increase in pRab1 levels that are reduced with MLi-2 (Figure 10D). In add-
ition to marked elevation of pRab10 phosphorylation in VPS35[D620N] neutrophils, we observed up to 6-fold
increases in pRab8 (Figure 10C) and pRab43 (Figure 10B). It would be important to extend this work with a
greater number of subjects in future studies. We speculate that the VPS35[D620N] mutation may enhance the
localization of LRRK2 at a membrane compartment containing Rab1. Is it also possible that differences in
effector binding affinity could influence the steady state phospho-Rab1 levels in cells by competing with
kinases and phosphatases targeting the Switch-II site. The latter point is also likely to be relevant for other Rab
proteins and warrants further analysis [46].
In conclusion, we describe a versatile new assay that enables the relative quantification of the key compo-
nents of the LRRK2 pathway, namely pRabs, pSer910/pSer935-LRRK2 as well as total Rab proteins and LRRK2
to be robustly quantified in cells and tissues. We demonstrate that this assay also works well to monitor the
LRRK2 pathway in human neutrophils and shows strong suitability to analyze clinical samples. In our view,
this assay provides significantly richer information than can be obtained by immunoblotting in terms of how
modulation of LRRK2 signalling pathway influences the phosphorylation of different Rab proteins.
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